Lobbying Relationship

Client

Lundbeck, Inc.

Pharmaceutical company More records

Lobbying firm

POLICY IMPACT COMMUNICATIONS, INC.

More records

  • HR 3200 -- Access to and coverage of Specialty Pharmaceuticals, Removal of patient life time caps and special tiering of copayments. S. 301 Physician payments and transparency, preemption of state law. America's Heathy Future Act of 2009
  • S. 525 and HR 1298 Drug Reimportation and impact on in-licensed and out-licensed products. HR 1427, HR 1548, S. 726 Biosimilar prescription drugs and data exclusivity.

Duration: to

General Issues: Health Issues, Trade (Domestic & Foreign), Taxation/Internal Revenue Code

Spending: about $120,000 (But it's complicated. Here's why.)

Agencies lobbied since 2009: House of Representatives, Senate

Related Foreign Entities: H. Lundbeck A/S (Copenhagen Valby, DK); contribution to lobbying: $0; ownership 100%

Bills mentioned

H.R.3200: America's Affordable Health Choices Act of 2009

Sponsor: John D. Dingell (D-Mich.)

S.301: Physician Payments Sunshine Act of 2009

Sponsor: Charles E. Grassley (R-Iowa)

S.525: Pharmaceutical Market Access and Drug Safety Act of 2009

Sponsor: Byron L. Dorgan (D-N.D.)

H.R.1298: Pharmaceutical Market Access and Drug Safety Act of 2009

Sponsor: Marion Berry (D-Ark.)

H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act

Sponsor: Henry A. Waxman (D-Calif.)

H.R.1548: Pathway for Biosimilars Act

Sponsor: Anna G. Eshoo (D-Calif.)

S.726: Promoting Innovation and Access to Life-Saving Medicine Act

Sponsor: Charles E. Schumer (D-N.Y.)

Show All Mentioned Bills

Lobbyists

Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.

Lobbyist Covered positions?
John M. Haddow Legislative Assistant
William Nixon Senior Policy Advisor/Communications Director
Matthew Salmon U.S. Representative from Arizona's 1st District
John Drew Hiatt Staff Director for the Small Business District

Disclosures Filed

Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.

Termination
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Registration
Registration

Source: Clerk of the U.S. House of Representatives and Secretary of the Senate

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print Google News logo Google_NewsInitiative_Lockup_FullColor RSS Search Search Twitter WhatsApp Resolving differences Check Building Arrow right Info circle Oops OOPS Pencil File text Bars Search Close Cogs Filter Compare Revolving Door Info card Activity Member menu Globe Document External link Quote News Calendar No Vote
Current site Current page